MediciNova, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving MediciNova, Inc. now
Current reporting with the operating signal separated from the noise.
MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients
The story matters when it changes MediciNova, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MediciNova, Inc.: MediciNova Provides Shareholder Update on Key Developments
Investors are testing whether MediciNova, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001
The story matters when it changes MediciNova, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest MNOV filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
MediciNova, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →